Printed From BioPortfolio.com
Merck’s Keytruda Significantly Improved Overall Survival and Progression-Free Survival in Late-Stage Lung Cancer Study
10:21 EST 16 Jan 2018 | Speciality Pharma Journal
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-189 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed (Alimta®) and cisplatin or carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), met its dual primary endpoints …
Original Article: Merck’s Keytruda Significantly Improved Overall Survival and Progression-Free Survival in Late-Stage Lung Cancer Study
